A new lung cancer pill from AstraZeneca has been approved by US regulators, in a major boost for the British drugmaker.
AZD9291, which will be sold as Tagrisso, is for advanced
non-small-cell lung cancer, the most common form of lung cancer.
Tagrisso targets a genetic mutation, known as T790M, that helps tumours
evade current lung cancer pills. The drug will be made available to
patients in the US as soon as possible and its price will be “comparable
to other oral cancer therapies,” a spokeswoman said. AstraZeneca will
reveal the price early next week.
Its approval means AstraZeneca has taken another step forward in its
ambition to bring six new cancer treatments to patients by 2020,
following the recent launch of Lynparza for ovarian cancer in the US.
The approval comes just two-and-a-half years since Tagrisso was first
tested on humans. It had received breakthrough status in the US and has
also received accelerated assessment in the EU following its filing in
the summer, as well as priority review in Japan.
No comments:
Post a Comment